Jiangsu Kanion Pharmaceutical (600557) Fundamentals 2026 — P/E 24.8x, Revenue Analysis | SniperIQ
Jiangsu Kanion Pharmaceutical (600557) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥7.3B, trading at ¥12.89 on the SHH. This SniperIQ fundamentals page covers Jiangsu Kanion Pharmaceutical's valuation (P/E 24.8x, P/B 1.5x), profitability (net margin 9.2%), revenue (¥3.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jiangsu Kanion Pharmaceutical's market cap?
Jiangsu Kanion Pharmaceutical (600557) has a market capitalization of approximately ¥7.3B, trading at ¥12.89 on the SHH. Market cap moves with the live share price.
What is Jiangsu Kanion Pharmaceutical's P/E ratio?
Jiangsu Kanion Pharmaceutical's trailing twelve-month P/E ratio is 24.8x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jiangsu Kanion Pharmaceutical?
Jiangsu Kanion Pharmaceutical runs a net profit margin of 9.2%, a gross margin of 71.6%, and an operating margin of 11.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jiangsu Kanion Pharmaceutical generate?
Jiangsu Kanion Pharmaceutical reported revenue of ¥3.3B for fiscal year 2025, with net income of ¥304M and earnings per share (EPS) of 0.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jiangsu Kanion Pharmaceutical pay a dividend?
Jiangsu Kanion Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Jiangsu Kanion Pharmaceutical financially healthy?
Jiangsu Kanion Pharmaceutical carries a debt-to-equity ratio of 0.00x and a current ratio of 1.93x, with a market beta of 0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jiangsu Kanion Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jiangsu Kanion Pharmaceutical (600557) the key facts are: market cap ¥7.3B, P/E 24.8x, revenue ¥3.3B, 52-week range 10.69-20.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jiangsu Kanion Pharmaceutical's full fundamentals live
Get Jiangsu Kanion Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.